Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.73 |
| ▸ | TENT4A | Q5XG87 | 1/20 | 0.73 |
| ▸ | TENT4B | Q8NDF8 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21042821 | 0.95 | CYP2B6 (0.70) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21043161 | 0.95 | CYP2B6 (0.70) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21042820 | 0.95 | CYP2B6 (0.70) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21042818 | 0.94 | CYP2B6 (0.69) | CYP2B6TENT4ATENT4B | |
| SCHEMBL20576719 | 0.94 | CYP2B6 (0.69) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21042819 | 0.94 | CYP2B6 (0.69) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21043349 | 0.94 | CYP2B6 (0.69) | CYP2B6TENT4ATENT4B | |
| SCHEMBL20576077 | 0.94 | CYP2B6 (0.68) | CYP2B6TENT4ATENT4B | |
| SCHEMBL20576171 | 0.93 | CYP2B6 (0.67) | CYP2B6TENT4ATENT4B | |
| SCHEMBL20577396 | 0.93 | CYP2B6 (0.67) | CYP2B6TENT4ATENT4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694856-B1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-10-25 | — | — | EP | disclosed |
| CN-110066278-B | Fused tricyclic compound and application thereof in medicines | 广东东阳光药业有限公司 | 2021-06-08 | — | — | CN | disclosed |
| US-10966970-B2 | Fused tricyclic compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| WO-2019100735-A1 | FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10966970-B2 | Fused tricyclic compounds and uses thereof in medicine | SLC10A1, CYP11B2, CYP11B1 | CYP2B6 27/4885TENT4A 2645/4885TENT4B 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.